Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Assets Average (2022 - 2025)

Historic Assets Average for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $430.8 million.

  • Entrada Therapeutics' Assets Average fell 2418.47% to $430.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.8 million, marking a year-over-year decrease of 2418.47%. This contributed to the annual value of $497.8 million for FY2024, which is 3802.64% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Assets Average is $430.8 million, which was down 2418.47% from $467.6 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Assets Average high stood at $568.3 million for Q3 2024, and its period low was $263.3 million during Q4 2022.
  • Moreover, its 4-year median value for Assets Average was $480.9 million (2023), whereas its average is $444.3 million.
  • In the last 5 years, Entrada Therapeutics' Assets Average surged by 8123.28% in 2023 and then plummeted by 2418.47% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Assets Average stood at $263.3 million in 2022, then soared by 81.23% to $477.1 million in 2023, then rose by 13.28% to $540.5 million in 2024, then dropped by 20.28% to $430.8 million in 2025.
  • Its Assets Average stands at $430.8 million for Q3 2025, versus $467.6 million for Q2 2025 and $506.4 million for Q1 2025.